Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Merrimack Pharmaceuticals Inc (NQ: MACK ) N/A UNCHANGED Last Price Updated: 4:00 PM EDT, May 17, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open - Bid (Size) 15.15 (8) Ask (Size) 15.16 (1) Prev. Close 15.13 Today's Range N/A - N/A 52wk Range 12.00 - 15.89 Shares Outstanding 14,400,000 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News MACK Stock Earnings: Merrimack Pharmaceuticals Reported Results for Q1 2024 May 16, 2024 Merrimack Pharmaceuticals just reported results for the first quarter of 2024. Via InvestorPlace Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock May 10, 2024 From Merrimack Pharmaceuticals, Inc. Via Business Wire Performance More News Read More Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution May 09, 2024 From Merrimack Pharmaceuticals, Inc. Via Business Wire Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution April 30, 2024 From Merrimack Pharmaceuticals, Inc. Via Business Wire Merrimack Receives $225 Million Milestone Payment from Ipsen March 27, 2024 From Merrimack Pharmaceuticals, Inc. Via Business Wire Merrimack Pharmaceuticals Inc. (NASDAQ: MACK) Highlighted for Surprising Price Action March 25, 2024 Via Investor Brand Network MACK Stock Earnings: Merrimack Pharmaceuticals Reported Results for Q4 2023 March 08, 2024 Via InvestorPlace Merrimack Reports Full Year 2023 Financial Results March 07, 2024 From Merrimack Pharmaceuticals, Inc. Via Business Wire Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) February 13, 2024 From Merrimack Pharmaceuticals, Inc. Via Business Wire $2M Bet On Ford? Check Out These 4 Stocks Insiders Are Buying December 12, 2023 Via Benzinga Merrimack Reports Third Quarter 2023 Financial Results November 02, 2023 From Merrimack Pharmaceuticals, Inc. Via Business Wire Pancreatic Cancer Battle Boosted by $200M VC Firm September 19, 2023 Via FinancialNewsMedia Topics Death Exposures Death Merrimack Reports Second Quarter 2023 Financial Results August 03, 2023 From Merrimack Pharmaceuticals, Inc. Via Business Wire Merrimack Reports First Quarter 2023 Financial Results May 04, 2023 From Merrimack Pharmaceuticals, Inc. Via Business Wire Why Jounce Therapeutics Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket March 15, 2023 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday March 15, 2023 Via InvestorPlace Luna Innovations, Guess? And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session March 15, 2023 Via Benzinga Merrimack Reports Full Year 2022 Financial Results March 09, 2023 From Merrimack Pharmaceuticals, Inc. Via Business Wire 3 Stocks Insiders Are Buying: Triumph Financial And More February 01, 2023 Via Benzinga $2.6M Bet On This Energy Stock? Check Out These 3 Stocks Insiders Are Buying January 18, 2023 Via Benzinga Insiders Buying Heska, B. Riley Financial And 2 Other Stocks January 10, 2023 Via Benzinga $1.4 Million Bet On Joint Corp? Check Out These 3 Stocks Insiders Are Buying January 04, 2023 Via Benzinga Merrimack Pharmaceuticals Extends Section 382 Net Operating Loss Rights Plan December 05, 2022 From Merrimack Pharmaceuticals, Inc. Via Business Wire Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer November 15, 2022 Via FinancialNewsMedia Topics Death Exposures Death Biotechs with Evolving Therapies Have Potential to Revolutionize Treatments for Pancreatic Cancer November 10, 2022 Via FinancialNewsMedia Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.